PHAS - PhaseBio Pharmaceuticals GAAP EPS of -$0.23 beats by $0.43
PhaseBio Pharmaceuticals press release (NASDAQ:PHAS): Q1 GAAP EPS of -$0.23 beats by $0.43. Cash and cash equivalents on March 31, 2022, were $18.7 million, compared to $41.8 million at December 31, 2021. Shares +9.52% PM.
For further details see:
PhaseBio Pharmaceuticals GAAP EPS of -$0.23 beats by $0.43